Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

Biomea Fusion presented clinical and translational data for icovamenib at the ADA 86th Scientific Sessions, demonstrating improvements in HbA1c and C-peptide levels in type 1 and type 2 diabetes patients, along with potential benefits for muscle preservation and fat reduction. The company also expanded its Phase I BMF-650 study to evaluate rapid titration schedules for its oral GLP-1 receptor agonist candidate.